<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Out of a series of 427 NHML based on the Kiel classification and without previous treatment, 186 were of high grade <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> and among them were 83 lymphoblastic (LB) and 58 immunoblastic (IB) <z:hpo ids='HP_0002665'>lymphomas</z:hpo> which were included in this study </plain></SENT>
<SENT sid="1" pm="."><plain>The LB and IB, which represent the majority of high grade NHML, were compared regarding their clinical features and courses </plain></SENT>
<SENT sid="2" pm="."><plain>Eight main criteria were significantly different between these two groups: age of patient, immunological history, mediastinal and pleural involvement, primary or secondary involvement of the bone marrow, secondary <z:mpath ids='MPATH_336'>leukaemia</z:mpath>, secondary meningeal involvement, and involvement of the facial region </plain></SENT>
<SENT sid="3" pm="."><plain>Some of these differences (mediastinum and meningeal involvement) are related to subtypes within LB </plain></SENT>
<SENT sid="4" pm="."><plain>The differences between these two groups suggest that different treatment programs may be warranted </plain></SENT>
</text></document>